Which has higher valuation and earnings, AZN or AMGN?

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.22 $10.23B $6.69 23.91 Amgen $36.75B 5.55 $7.71B $16.09 23.45

Is AZN or AMGN more profitable?

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Amgen 22.95% 124.14% 13.18%

Does the media refer more to AZN or AMGN?

In the previous week, Amgen had 29 more articles in the media than Astrazeneca. MarketBeat recorded 58 mentions for Amgen and 29 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.53 beat Amgen's score of 0.19 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 11 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive Amgen 14 Very Positive mention(s) 8 Positive mention(s) 18 Neutral mention(s) 11 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has better earnings and valuation, BIIB or AZN?

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.24 $1.29B $5.65 38.43 Astrazeneca $58.74B 4.22 $10.23B $6.69 23.91

Is BIIB or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Astrazeneca 17.02% 31.45% 13.20%

Does the media favor BIIB or AZN?

In the previous week, Astrazeneca had 20 more articles in the media than Biogen. MarketBeat recorded 29 mentions for Astrazeneca and 9 mentions for Biogen. Biogen's average media sentiment score of 1.23 beat Astrazeneca's score of 0.53 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 11 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MRNA or AZN?

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 29.57 -$2.82B -$7.99 N/A Astrazeneca $58.74B 4.22 $10.23B $6.69 23.91

Is MRNA or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Astrazeneca 17.02% 31.45% 13.20%

Does the media favor MRNA or AZN?

In the previous week, Astrazeneca had 8 more articles in the media than Moderna. MarketBeat recorded 29 mentions for Astrazeneca and 21 mentions for Moderna. Astrazeneca's average media sentiment score of 0.53 beat Moderna's score of 0.46 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 7 Very Positive mention(s) 8 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Astrazeneca 11 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive

Which has better earnings & valuation, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.22 $10.23B $6.69 23.91 Novavax $1.12B 1.38 $440.30M -$1.52 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Novavax -59.87% -14.82% -13.35%

Does the media prefer AZN or NVAX?

In the previous week, Astrazeneca had 16 more articles in the media than Novavax. MarketBeat recorded 29 mentions for Astrazeneca and 13 mentions for Novavax. Astrazeneca's average media sentiment score of 0.53 beat Novavax's score of 0.44 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 11 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive Novavax 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AZN or ABBV?

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.22 $10.23B $6.69 23.91 AbbVie $61.16B 7.43 $4.23B $3.54 72.65

Is AZN or ABBV more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% AbbVie 9.80% -422.07% 14.34%

Does the media prefer AZN or ABBV?

In the previous week, AbbVie had 44 more articles in the media than Astrazeneca. MarketBeat recorded 73 mentions for AbbVie and 29 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.28 beat Astrazeneca's score of 0.53 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 11 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive AbbVie 55 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Astrazeneca (AZN) Competitors

$159.98 -0.20 (-0.12%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$163.24 +3.26 (+2.04%)

As of 08:22 AM Eastern

Compare

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy Astrazeneca stock or one of its competitors? Astrazeneca's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Astrazeneca compare to Amgen?

Astrazeneca (NYSE:AZN) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Amgen	22.95%	124.14%	13.18%

Astrazeneca has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

In the previous week, Amgen had 29 more articles in the media than Astrazeneca. MarketBeat recorded 58 mentions for Amgen and 29 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.53 beat Amgen's score of 0.19 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	11 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive
Amgen	14 Very Positive mention(s)	8 Positive mention(s)	18 Neutral mention(s)	11 Negative mention(s)	4 Very Negative mention(s)	Neutral

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.22	$10.23B	$6.69	23.91
Amgen	$36.75B	5.55	$7.71B	$16.09	23.45

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 29.19%. Amgen has a consensus price target of $381.68, suggesting a potential upside of 1.15%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years.

Summary

Amgen beats Astrazeneca on 11 of the 20 factors compared between the two stocks.

How does Astrazeneca compare to Biogen?

Biogen (NASDAQ:BIIB) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43
Astrazeneca	$58.74B	4.22	$10.23B	$6.69	23.91

Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Astrazeneca had 20 more articles in the media than Biogen. MarketBeat recorded 29 mentions for Astrazeneca and 9 mentions for Biogen. Biogen's average media sentiment score of 1.23 beat Astrazeneca's score of 0.53 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	11 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biogen currently has a consensus target price of $230.14, suggesting a potential upside of 5.98%. Astrazeneca has a consensus target price of $206.67, suggesting a potential upside of 29.19%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts plainly believe Astrazeneca is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Astrazeneca	17.02%	31.45%	13.20%

Summary

Astrazeneca beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to Moderna?

Moderna (NASDAQ:MRNA) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	29.57	-$2.82B	-$7.99	N/A
Astrazeneca	$58.74B	4.22	$10.23B	$6.69	23.91

In the previous week, Astrazeneca had 8 more articles in the media than Moderna. MarketBeat recorded 29 mentions for Astrazeneca and 21 mentions for Moderna. Astrazeneca's average media sentiment score of 0.53 beat Moderna's score of 0.46 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	7 Very Positive mention(s)	8 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Astrazeneca	11 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive

Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Moderna presently has a consensus price target of $76.72, suggesting a potential downside of 46.71%. Astrazeneca has a consensus price target of $206.67, suggesting a potential upside of 29.19%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

75.3% of Moderna shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Astrazeneca	17.02%	31.45%	13.20%

Summary

Astrazeneca beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to Novavax?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.22	$10.23B	$6.69	23.91
Novavax	$1.12B	1.38	$440.30M	-$1.52	N/A

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novavax	-59.87%	-14.82%	-13.35%

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 29.19%. Novavax has a consensus price target of $14.00, suggesting a potential upside of 48.62%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Astrazeneca has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

In the previous week, Astrazeneca had 16 more articles in the media than Novavax. MarketBeat recorded 29 mentions for Astrazeneca and 13 mentions for Novavax. Astrazeneca's average media sentiment score of 0.53 beat Novavax's score of 0.44 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	11 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Astrazeneca beats Novavax on 12 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to AbbVie?

Astrazeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
AbbVie	9.80%	-422.07%	14.34%

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.22	$10.23B	$6.69	23.91
AbbVie	$61.16B	7.43	$4.23B	$3.54	72.65

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 29.19%. AbbVie has a consensus price target of $276.64, suggesting a potential upside of 7.57%. Given Astrazeneca's higher possible upside, equities research analysts clearly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, AbbVie had 44 more articles in the media than Astrazeneca. MarketBeat recorded 73 mentions for AbbVie and 29 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.28 beat Astrazeneca's score of 0.53 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	11 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive
AbbVie	55 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years. Astrazeneca is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get Astrazeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	Astrazeneca	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$248.11B	$12.45B	$7.15B	$23.34B
Dividend Yield	2.71%	2.64%	2.57%	3.57%
P/E Ratio	23.91	799.76	275.24	28.72
Price / Sales	4.22	756.88	647.32	21.23
Price / Cash	12.39	14.86	28.42	19.47
Price / Book	5.09	10.37	10.33	4.75
Net Income	$10.23B	$2.85B	$3.50B	$1.07B
7 Day Performance	-1.63%	-3.62%	-3.32%	-2.00%
1 Month Performance	2.30%	0.47%	-0.87%	-3.27%
1 Year Performance	N/A	3.56%	23.52%	10.51%

Astrazeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN Astrazeneca	4.8767 of 5 stars	$159.98 -0.1%	$206.67 +29.2%	N/A	$248.11B	$58.74B	23.91	96,100	Analyst Revision
AMGN Amgen	3.5474 of 5 stars	$377.35 -1.3%	$381.68 +1.1%	+36.5%	$204.01B	$36.75B	23.45	31,500	Trending News Gap Up
BIIB Biogen	3.3 of 5 stars	$217.15 +0.8%	$230.14 +6.0%	+49.9%	$32.08B	$9.89B	38.43	7,500	Positive News
MRNA Moderna	2.1297 of 5 stars	$143.97 +5.4%	$76.72 -46.7%	+512.4%	$57.48B	$1.94B	N/A	4,700	Gap Down
NVAX Novavax	2.0786 of 5 stars	$9.42 +1.3%	$14.00 +48.6%	+18.0%	$1.55B	$1.12B	N/A	1,990	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AZN) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrazeneca (AZN) Competitors